Management of Ewing sarcoma family of tumors: Current scenario and unmet need

Table 2 Euro-Ewing 99 trial design and details

Randomized arm	Patients	n	Randomization	3-yr EFS
Arm 1	SR, Localized (good histologic response, < 200 mL + RT)	856	6#VIDE + 1#VAI f/b 7#VAI vs 7#VAC	78% vs 75%
Arm 2	HR, Localized (poor histologic response, ≥ 200 mL and RT alone)	---	6#VIDE + 1#VAI f/b 7# VAI vs BuMel (n = 281)	45% (BuMel)
	Lung metastasis only	---	6#VIDE + 1#VAI f/b 7# VAI + WLI vs BuMel	---
Arm 3	Extrapulmonary metastasis	---	6#VIDE + 1#VAI f/b BuMel/TreoMel vs clinical trial	---

BuMel: Busulphan and melphalan; EFS: Event free survival; f/b: Followed-by; HR: High risk; n: Number; RT: Radiotherapy; SR: Standard risk; TreoMel: Tresulphan and melphalan; VAC: Vincristine, dactinomycin, cyclophosphamide; VAI: Vincristine, dactinomycin, ifosfamide; VIDE: Vincristine, ifosfamide, doxorubicin, etoposide; WLI: Whole lung irradiation.